Trial readouts
What the latest Phase 2 and Phase 3 trials reported, the effect sizes that matter, and how to read the safety signals around them.
GLP-1 Safety Signals in FAERS
A 2026 GLP-1 pharmacovigilance study used sensitivity tests and a second database to separate stable safety signals from fragile ones.
GLP-1 drugs and inflammation markers
A 2026 meta-analysis linked GLP-1 therapies to changes in selected inflammation and metabolic biomarkers in type 2 diabetes.
TB Meningitis Drug Screen: Study Results
A 2026 study tested semaglutide and other host-directed treatments for TB meningitis across mice, brain organoids and patient cells.
Zalfermin Combo Missed Its Endpoint
A phase 2 trial found no significant fibrosis benefit from adding zalfermin to semaglutide across F2 to compensated F4 MASH.
Semaglutide Hydrogel Tested in Rats
A preclinical rat study tested a thermosensitive semaglutide hydrogel. It cannot establish human efficacy, dosing, or safety.
Semaglutide and PPGL Cells: New Data
A laboratory study found different semaglutide effects across patient-derived PPGL cultures, including a signal in three RET-linked tumors.
Semaglutide vs Resmetirom in MASH
An indirect comparison favoured semaglutide on one MASH endpoint but cannot replace a randomized head-to-head trial.
Tirzepatide and MASLD in Mice
A mouse and cell study linked tirzepatide with less liver fat and inflammation, with Dectin-1 signaling proposed as part of the mechanism.
Tirzepatide Safety Signals in FAERS
A 2026 review found lower kidney-injury reporting and no significant suicidality signal for tirzepatide, with major FAERS limits.
GLP-1 Drugs and Neuroinflammation
A 2026 review links GLP-1 drugs to immune pathways in the brain, but human trials have not established a general neurological benefit.
GLP-1 safety cohort: what it found
A 2026 South Korean cohort linked semaglutide and liraglutide initiation with selected safety outcomes, without proving causation.
Personalising Tirzepatide Maintenance
A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.